mResvia has been approved in the EU since 2024 to protect adults aged 60 years and older against lower respiratory tract ...

Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...

Shares in AstraZeneca were trading down more than 8% this morning after it revealed that its transthyretin amyloidosis (ATTR) ...

The drugmaker – which was known as Mallinckrodt beforemerging with Endo and rebranding as Keenova last year – said that ...

Alector has confirmed that an alliance with GSK to develop two drug candidates for dementia has been terminated in the wake ...

B inhibitor Jascayd (nerandomilast) has been cleared as a twice-daily, oral therapy for adults with IPF as well as ...

The EMA's human medicines committee has started a review of oral complement C5 inhibitor Tavneos, prompted by information that the regulator says raises questions about the integrity of the data from ...

Hengrui and Kailera have been vocal about positioning the drug as being capable of improving the clinical profile of existing ...

In another big-ticket licensing deal with a Chinese biotech, AstraZeneca has claimed rights to a drug candidate for chronic ...

Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgA nephropathy (IgAN) that will compete with ...

At the moment, many of the big AI systems used in drug discovery are closed-source, meaning they are proprietary and carry an ...

The Evolution Summit is structured around a dynamic agenda of visionary keynote presentations, real-life case studies, and ...